| Placebo (mg) | Tolvaptan | P value | |||||||
---|---|---|---|---|---|---|---|---|---|---|
7.5Â mg/day | 15Â mg/day | Â | ||||||||
Mean ± SD | Changes from baseline | Mean ± SD | Changes from baseline | Mean ± SD | Changes from baseline | 7.5 mg tolvaptan versus placebo | 15.0 mg tolvaptan versus placebo | 7.5 mg versus 15.0 mg tolvaptan | ||
All patients (N) | 76 | 153 | 301 | Â | Â | Â | ||||
Serum Na+ concentration (mmol/L) | Baseline | 137.7 ± 4.4 | – | 136.7 ± 5.1 | – | 136.9 ± 4.8 | – | – | – | – |
4–8 h | 136.2 ± 5.2 | − 1.4 ± 3.1 | 137.7 ± 5.9 | 1.0 ± 3.6 | 138.2 ± 5.8 | 1.3 ± 3.8 | < 0.001 | < 0.001 | 0.408 | |
Day 1 | 137.6 ± 4.6 | − 0.1 ± 2.8 | 138.8 ± 5.4 | 2.0 ± 3.4 | 140.3 ± 4.9 | 3.4 ± 3.4 | < 0.001 | < 0.001 | < 0.001 | |
Day 4 | 137.4 ± 5.1 | − 0.3 ± 3.14 | 138.3 ± 5.1 | 1.6 ± 3.0 | 139.6 ± 4.7 | 2.7 ± 3.9 | < 0.001 | < 0.001 | 0.002 | |
Day 7 | 137.0 ± 5.1 | − 0.7 ± 3.4 | 138.2 ± 5.1 | 1.4 ± 3.3 | 139.0 ± 4.6 | 2.1 ± 4.0 | < 0.001 | < 0.001 | 0.075 | |
Serum K+ concentration (mmol/L) | Baseline | 3.9 ± 0.5 | – | 4.1 ± 0.6 | – | 4.0 ± 0.5 | – | – | – | – |
Day 4 | 4.0 ± 0.7 | 0.1 ± 0.5 | 4.2 ± 0.4 | 0.1 ± 0.5 | 4.2 ± 0.7 | 0.1 ± 0.7 | 0.752 | 0.845 | 0.494 | |
Day 7 | 4.0 ± 0.5 | 0.1 ± 0.5 | 4.2 ± 0.5 | 0.1 ± 0.5 | 4.2 ± 0.5 | 0.2 ± 0.6 | 0.885 | 0.390 | 0.199 | |
Hyponatremia patients (Na+ baseline< 135 mmol/L) (N) | 17 | 41 | 85 |  | ||||||
Serum Na+ concentration (mmol/L) | Baseline | 131.3 ± 3.1 | – | 130.2 ± 4.5 | – | 130.9 ± 3.7 | – | – | – | – |
4–8 h | 129.4 ± 4.6 | − 1.9 ± 3.7 | 131.1 ± 5.7 | 1.0 ± 3.9 | 132.7 ± 6.2 | 1.8 ± 4.3 | 0.019 | < 0.001 | 0.260 | |
Day 1 | 132.6 ± 4.9 | 1.2 ± 3.7 | 133.5 ± 6.0 | 3.3 ± 3.8 | 135.6 ± 5.1 | 4.7 ± 3.7 | 0.061 | < 0.001 | 0.057 | |
Day 4 | 131.2 ± 5.0 | − 0.1 ± 4.6 | 133.2 ± 5.9 | 3.0 ± 3.2 | 135.4 ± 5.1 | 4.5 ± 4.6 | 0.013 | < 0.001 | 0.063 | |
Day 7 | 130.3 ± 4.7 | − 1.0 ± 4.1 | 132.8 ± 5.2 | 2.6 ± 3.2 | 134.9 ± 4.9 | 4.0 ± 5.1 | 0.005 | < 0.001 | 0.144 |